Technology areas: Biotechnology & Pharmaceuticals • Semiconductors, Circuits & Optics
55 pending office actions • 31 clients • 54 examiners • 37 art units • 0 of 55 (0%) have an AI response strategy ready
Junhe Law Office P.C. has 54 pending office actions in Biotechnology & Pharmaceuticals and 1244 career applications. Its resolved allowance rate is 90.39%, with an average of 3.66 office actions per allowance. The record therefore combines a substantial historical application base with an active current workload.
The allowance rate is a resolved-matter measure and should not be read as a prediction for an individual application. The office-action average indicates that allowance commonly follows multiple examination events in the recorded portfolio. For patent practitioners, the data supports a prosecution strategy that preserves flexibility across amendments and responses while recognizing the firm’s biotechnology and pharmaceutical focus.
Based on the USPTO statutory response window for each pending office action. 8 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 8 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 4 (7%) |
| §103 only | 15 (27%) |
| §102 only | 1 (2%) |
| §112 only | 8 (15%) |
| Double-patenting only | 1 (2%) |
| Double-patenting + other | 6 (11%) |
| Multi-statute (no §101) | 20 (36%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MALSAWMA, LALRINFAMKIM HMAR | 2 | 90.4% | +8.1% |
| STONER, KILEY SHAWN | 1 | 80.8% | +15.4% |
| KORTMAN, CURTIS JAMES | 1 | 79.5% | +24.1% |
| FAIRCHILD, MALLIKA DIPAYAN | 1 | 79.5% | +18.2% |
| KONOPELSKI SNAVEL, SARA ELIZABETH | 1 | 35.0% | +35.4% |
| CORNET, JEAN P | 1 | 41.9% | +47.2% |
| ROBINSON, HOPE A | 1 | 67.7% | +43.0% |
| HUTCHESON, CODY DOUGLAS | 1 | 58.8% | +28.5% |
| GEMBEH, SHIRLEY V | 1 | 63.1% | +33.8% |
| STARK, JARRETT J | 1 | 70.4% | +11.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18605841 | INTEGRATED PACKAGE AND METHOD FOR MAKING THE SAME | MALSAWMA, LALRINFAMKIM HMAR | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16918958 | HIGH CAPACITY MOLECULE DETECTION | POHNERT, STEVEN C | 202d overdue |
| 19452282 | SELECTIVE STENCIL MASK AND A STENCIL PRINTING METHOD | STONER, KILEY SHAWN | — |
| 19218586 | MEMORY SYSTEM, COMPUTER SYSTEM AND DATA INTERACTION METHOD | KORTMAN, CURTIS JAMES | — |
| 18730790 | TRUNCATED FORMS OF IGA PROTEASE, FUSION PROTEINS COMPRISING A TRUNCATED FORM OF IGA PROTEASE AND USES THEREOF | ROBINSON, HOPE A | — |
| 18725147 | METHOD AND DEVICE FOR GENERATING SPEECH ENHANCEMENT MODEL, AND SPEECH ENHANCEMENT METHOD AND DEVICE | HUTCHESON, CODY DOUGLAS | — |
| 18749657 | SEMICONDUCTOR PACAKGE AND METHOD FOR FORMING THE SAME | STARK, JARRETT J | — |
| 18749572 | DENTAL APPLIANCE SYSTEM AND AN ORTHODONTIC METHOD USING THE SAME | NELSON, MATTHEW M | — |
| 18740630 | SEMICONDUCTOR PACKAGES WITH MULTIPLE TYPES OF CONDUCTIVE COMPONENTS | SENGDARA, VONGSAVANH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19452282 | SELECTIVE STENCIL MASK AND A STENCIL PRINTING METHOD | STONER, KILEY SHAWN | — |
| 19218586 | MEMORY SYSTEM, COMPUTER SYSTEM AND DATA INTERACTION METHOD | KORTMAN, CURTIS JAMES | — |
| 18869848 | IMPLANTABLE HEART FAILURE TREATMENT DEVICE | FAIRCHILD, MALLIKA DIPAYAN | — |
| 18836758 | METHODS FOR TREATING CATARACTS USING POLYPEPTIDES | KONOPELSKI SNAVEL, SARA ELIZABETH | — |
| 18832936 | PHARMACEUTICAL COMPOSITION OF ANTIPLATELET DRUG, AND USE THEREOF | CORNET, JEAN P | — |
| 18730790 | TRUNCATED FORMS OF IGA PROTEASE, FUSION PROTEINS COMPRISING A TRUNCATED FORM OF IGA PROTEASE AND USES THEREOF | ROBINSON, HOPE A | — |
| 18725147 | METHOD AND DEVICE FOR GENERATING SPEECH ENHANCEMENT MODEL, AND SPEECH ENHANCEMENT METHOD AND DEVICE | HUTCHESON, CODY DOUGLAS | — |
| 18754130 | COMBINATION OF BCL-2/BCL-XL INHIBITORS AND CHEMOTHERAPEUTIC AGENT AND USE THEREOF | GEMBEH, SHIRLEY V | — |
| Art Unit | Apps |
|---|---|
| 2893 | 5 |
| 2818 | 5 |
| 2812 | 3 |
| 1624 | 2 |
| 2892 | 2 |
| 1647 | 2 |
| 1675 | 2 |
| 1644 | 2 |
| 2899 | 2 |
| 1735 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19452282 | SELECTIVE STENCIL MASK AND A STENCIL PRINTING METHOD | Stats Chippac Pte. Ltd. | STONER, KILEY SHAWN | 1735 | §102§103§112 | Non-Final OA | — | Pending | Jan 17, 2026 |
| 19218586 | MEMORY SYSTEM, COMPUTER SYSTEM AND DATA INTERACTION METHOD | Montage Technology (Kunshan) Co., Ltd. | KORTMAN, CURTIS JAMES | 2139 | §103§112 | Non-Final OA | — | Pending | May 26, 2025 |
| 18869848 | IMPLANTABLE HEART FAILURE TREATMENT DEVICE | UNITED INNOMED (SHANGHAI) LIMITED | FAIRCHILD, MALLIKA DIPAYAN | 3792 | §112 | Non-Final OA | — | Pending | Nov 27, 2024 |
| 18836758 | METHODS FOR TREATING CATARACTS USING POLYPEPTIDES | Rejukon Biopharm Inc. | KONOPELSKI SNAVEL, SARA ELIZABETH | 1658 | §102§103§112DP | Non-Final OA | — | Pending | Aug 08, 2024 |
| 18832936 | PHARMACEUTICAL COMPOSITION OF ANTIPLATELET DRUG, AND USE THEREOF | Shanghai Curegene Pharmaceutical Co., Ltd. | CORNET, JEAN P | 1628 | §103 | Non-Final OA | — | Pending | Jul 25, 2024 |
| 18730790 | TRUNCATED FORMS OF IGA PROTEASE, FUSION PROTEINS COMPRISING A TRUNCATED FORM OF IGA PROTEASE AND USES THEREOF | Shanghai Alezyme Pharmaceuticals Ltd. | ROBINSON, HOPE A | 1652 | §103§112 | Non-Final OA | — | Pending | Jul 22, 2024 |
| 18725147 | METHOD AND DEVICE FOR GENERATING SPEECH ENHANCEMENT MODEL, AND SPEECH ENHANCEMENT METHOD AND DEVICE | Orka Health Co., Ltd. | HUTCHESON, CODY DOUGLAS | 2659 | §101§103 | Non-Final OA | — | Pending | Jun 28, 2024 |
| 18754130 | COMBINATION OF BCL-2/BCL-XL INHIBITORS AND CHEMOTHERAPEUTIC AGENT AND USE THEREOF | Ascentage Pharma (Suzhou) Co., Ltd. | GEMBEH, SHIRLEY V | 1615 | §103DP | Final Rejection | — | Pending | Jun 25, 2024 |
| 18749657 | SEMICONDUCTOR PACAKGE AND METHOD FOR FORMING THE SAME | Stats Chippac Pte. Ltd. | STARK, JARRETT J | 2898 | §103§112 | Non-Final OA | — | Pending | Jun 21, 2024 |
| 18749572 | DENTAL APPLIANCE SYSTEM AND AN ORTHODONTIC METHOD USING THE SAME | Wuxi Ea Medical Instruments Technologies Limited | NELSON, MATTHEW M | 3772 | §101§102 | Final Rejection | — | Pending | Jun 20, 2024 |
| 18740630 | SEMICONDUCTOR PACKAGES WITH MULTIPLE TYPES OF CONDUCTIVE COMPONENTS | Stats Chippac Pte. Ltd. | SENGDARA, VONGSAVANH | 2893 | §102§103 | Non-Final OA | — | Pending | Jun 12, 2024 |
| 18731402 | Chimeric Natural Killer Cell Receptors and Method of Using Thereof | St Phi Therapeutics Co., Ltd. | KAUFMAN, CLAIRE M | 1674 | §103 | Final Rejection | 37d overdue | Pending | Jun 03, 2024 |
| 18670747 | SEMICONDUCTOR PACKAGE WITH IMPROVED HEAT DISSIPATION | Jcet Stats Chippac Korea Limited | WIEGAND, TYLER J | 2812 | §102§112 | Non-Final OA | — | Pending | May 22, 2024 |
| 18709820 | COMPOUND FOR REDUCING URIC ACID LEVELS | Newsoara Biopharma Co., Ltd. | BRAUN, MADELINE E | 1624 | §103§112 | Final Rejection | — | Pending | May 14, 2024 |
| 18661773 | ELECTRONIC PACKAGE AND METHOD FOR FORMING THE SAME | Stats Chippac Pte. Ltd. | HOQUE, MOHAMMAD M | 2817 | §112 | Non-Final OA | — | Pending | May 13, 2024 |
| 18655254 | ELECTRONIC PACKAGE AND A PACKAGING METHOD | Stats Chippac Pte. Ltd. | HARBOTTLE, CHARLOTTE ELIZABETH | 2818 | §103§112 | Non-Final OA | — | Pending | May 04, 2024 |
| 18646903 | SEMICONDUCTOR DEVICE AND METHOD FOR MAKING THE SAME | Stats Chippac Pte. Ltd. | THROCKMORTON, ROBERT EMIL | 2818 | §102§103 | Non-Final OA | — | Pending | Apr 26, 2024 |
| 18639994 | SEMICONDUCTOR DEVICE WITH A PARTIAL SHIELDING LAYER AND A METHOD FOR MAKING THE SAME | Jcet Stats Chippac Korea Limited | MUNOZ, ANDRES F | 2818 | §103 | Non-Final OA | — | Pending | Apr 19, 2024 |
| 18638733 | SEMICONDUCTOR DEVICE AND A METHOD FOR FORMING A SEMICONDUCTOR DEVICE | Stats Chippac Pte. Ltd. | TRAN, DZUNG | 2893 | §103 | Non-Final OA | — | Pending | Apr 18, 2024 |
| 18636301 | SEMICONDUCTOR PACKAGE STRIP AND METHOD FOR FORMING A SEMICONDUCTOR DEVICE | Jcet Stats Chippac Korea Limited | TURNER, BRIAN | 2818 | §102§103 | Final Rejection | — | Pending | Apr 16, 2024 |
| 18700268 | METHODS FOR DEVELOPING A CELL LINE FOR PRODUCING VIRUS IN SUSPENSION CELL CULTURE | Porton Advanced Solutions Ltd. | KIM, TAEYOON | 1631 | §103§112 | Non-Final OA | — | Pending | Apr 10, 2024 |
| 18697015 | HALOGENATED PHENYLARSINE OXIDE COMPOUND AND APPLICATION THEREOF | Nuo-Beta Pharmaceutical Technology (Shanghai) Co., Ltd. | HABTE, KAHSAY | 1624 | §102§112DP | Non-Final OA | — | Pending | Mar 29, 2024 |
| 18605841 | INTEGRATED PACKAGE AND METHOD FOR MAKING THE SAME | Stats Chippac Pte. Ltd. | MALSAWMA, LALRINFAMKIM HMAR | 2892 | §103 | Non-Final OA | — | Pending | Mar 15, 2024 |
| 18692340 | DRUG DELIVERY SYSTEM FOR LOCALLY DELIVERING THERAPEUTIC AGENTS AND USES THEREOF | Coval Biopharma (Shanghai) Co., Ltd. | SHIAO, YIH-HORNG | §102§103Other | Non-Final OA | — | Pending | Mar 15, 2024 | |
| 18605842 | PARTIALLY SHIELDED SEMICONDUCTOR DEVICE AND METHOD FOR MAKING THE SAME | Stats Chippac Pte. Ltd. | MALSAWMA, LALRINFAMKIM HMAR | 2892 | §102§103 | Non-Final OA | — | Pending | Mar 15, 2024 |
| 18597878 | SEMICONDUCTOR DEVICE WITH IMPROVED HEAT DISSIPATION AND METHOD FOR MAKING THE SAME | Jcet Stats Chippac Korea Limited | MAZUMDER, DIDARUL A | 2812 | §103 | Final Rejection | — | Pending | Mar 06, 2024 |
| 18292922 | NOVEL ANTI-SIRPA ANTIBODIES | Elpiscience Biopharma, Ltd. | LANDSMAN, ROBERT S | 1647 | §112 | Non-Final OA | — | Pending | Jan 28, 2024 |
| 18292921 | NOVEL MULTI-SPECIFIC MOLECULES | Elpiscience Biopharma, Ltd. | REDDIG, PETER J | §102§103§112Other | Non-Final OA | — | Pending | Jan 28, 2024 | |
| 18575326 | NOVEL ANTI-MASP-2 ANTIBODIES | Suzhou Transcenta Therapeutics Co., Ltd. | STOICA, ELLY GERALD | 1647 | §112 | Non-Final OA | — | Pending | Dec 29, 2023 |
| 18395626 | SEMICONDUCTOR DEVICE AND METHOD FOR MAKING THE SAME | Stats Chippac Pte. Ltd. | NGUYEN, SOPHIA T | 2893 | §103§112 | Final Rejection | — | Pending | Dec 25, 2023 |
| 18395650 | ELECTRONIC DEVICE AND METHOD FOR MANUFACTURING THE SAME | Jcet Stats Chippac Korea Limited | TRAN, TAN N | 2812 | §103 | Final Rejection | — | Pending | Dec 25, 2023 |
| 18559795 | NOVEL ANTI-CD276 ANTIBODIES AND THE USES THEREOF | Antengene Biologics Limited | MOSELEY II, NELSON B | 1642 | §112 | Non-Final OA | — | Pending | Nov 09, 2023 |
| 18556665 | HETERODIMERIC ANTIBODIES AND ANTIGEN-BINDING FRAGMENT THEREOF | Chimagen Biosciences, Ltd. | CUNNINGCHEN, KATHLEEN MARY | 1646 | §102§103§112 | Non-Final OA | — | Pending | Oct 21, 2023 |
| 18555341 | NOVEL ANTI-HVEGFR2 ANTIBODIES | Suzhou Transcenta Therapeutics Co., Ltd. | BALLARD, KIMBERLY | 1675 | §112 | Non-Final OA | — | Pending | Oct 13, 2023 |
| 18469536 | METHOD FOR MAKING AN ELECTRONIC PACKAGE | Jcet Stats Chippac Korea Limited | NETTLES, CORALIE ANN | 2893 | §103 | Non-Final OA | 22d | Pending | Sep 18, 2023 |
| 18549928 | METHOD OF TREATING DISEASES USING GREMLIN1 ANTAGONISTS | Suzhou Transcenta Therapeutics Co., Ltd. | BELYAVSKYI, MICHAIL A | 1644 | §103DP | Final Rejection | — | Pending | Sep 11, 2023 |
| 18460621 | SEMICONDUCTOR DEVICE AND METHOD FOR MAKING THE SAME | Stats Chippac Pte. Ltd. | FAN, SU JYA | 2818 | §103 | Final Rejection | — | Pending | Sep 04, 2023 |
| 18459014 | SENSOR ASSEMBLY AND METHOD FOR FORMING THE SAME | Stats Chippac Pte. Ltd. | KUPP, BENJAMIN MICHAEL | 2893 | §103 | Final Rejection | 7d | Pending | Aug 30, 2023 |
| 18546980 | ANTI-CLDN18.2 ANTIBODY CONJUGATES | BEIJING CANCER HOSPITAL | DUNN, LINDSAY MICHELLE | 1644 | §102§103§112DP | Non-Final OA | — | Pending | Aug 18, 2023 |
| 18447315 | SEMICONDUCTOR DEVICES WITH PYRAMIDAL SHIELDING AND METHOD FOR MAKING THE SAME | Stats Chippac Pte. Ltd. | BULLARD-CONNOR, GENEVIEVE GRACE | 2899 | §103 | Final Rejection | 9d | Pending | Aug 10, 2023 |
| 18264765 | METHODS OF MODULATING ANDROGEN RECEPTOR CONDENSATES | Etern Therapeutics (Wuxi) Co., Ltd. | BELL, SARA ELIZABETH | 1625 | §102§103§112 | Non-Final OA | — | Pending | Aug 09, 2023 |
| 18264764 | METHODS FOR MODULATING A SRC-1 CONDENSATE | Etern Therapeutics Inc. | BERKE-SCHLESSEL, DAVID W | 1651 | §101§102§103§112 | Non-Final OA | — | Pending | Aug 09, 2023 |
| 18263088 | APPARATUS AND SYSTEMS FOR MONITORING AND TREATING CATARACTS | Edinburgh Biosciences Ltd. | FABIAN JR, ROBERTO | 2877 | §103 | Non-Final OA | 33d | Pending | Jul 26, 2023 |
| 18353863 | ELECTRONIC COMPONENTS WITH IMPROVED INSULATION, ELECTRONIC PACKAGES INCORPORATING SUCH ELECTRONIC COMPONENTS | Stats Chippac Pte. Ltd. | MELLINGER, CORBYN DAVID | 2899 | §102§112 | Non-Final OA | — | Pending | Jul 17, 2023 |
| 18338313 | NOVEL METHOD FOR PRODUCING ANTIBODIES | Tsinghua University | NATARAJAN, MEERA | 1643 | §103 | Non-Final OA | — | Pending | Jun 20, 2023 |
| 18254606 | NOVEL CONJUGATE MOLECULES TARGETING CD39 AND TGFBETA | Elpiscience Biopharma, Ltd. | HADDAD, MAHER M | 1641 | §102 | Final Rejection | — | Pending | May 26, 2023 |
| 18246516 | NOVEL ANTI-CLAUDIN18 ANTIBODIES | Elpiscience Biopharma, Ltd. | BERHANE, SELAM | 1675 | §112 | Final Rejection | 62d | Pending | Mar 24, 2023 |
| 18172322 | METHODS FOR DETECTING HOMOLOGOUS RECOMBINATION DEFICIENCY IN CANCER PATIENTS | Genegeniedx Corp. | HAYES, JONATHAN EDWARD | 1685 | §101§103§112 | Non-Final OA | — | Pending | Feb 22, 2023 |
| 18005356 | DRUG DELIVERY SYSTEM FOR LOCALLY DELIVERING THERAPEUTIC AGENTS AND USES THEREOF | Coval Biopharma (Shanghai) Co., Ltd. | BRANDSEN, BENJAMIN MICHAEL | 1693 | §103§112Other | Final Rejection | — | Pending | Jan 13, 2023 |
| 17624850 | MICROMOLECULE PI4KIIIalpha INHIBITOR COMPOSITION, PREPARATION METHOD THEREFOR AND USE THEREOF | Nuo-Beta Pharmaceutical Technology (Shanghaia) Co., Ltd. | YOUNGBLOOD, WILLIAM JUSTIN | 1629 | §103Other | Final Rejection | — | Pending | Nov 18, 2022 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial90.4% of resolved applications prosecuted by Junhe Law Office P.C. were allowed, across 1,244 applications in USPTO records.
3.66 office actions per allowed application on average.
55 pending office actions as of October 2026, for 31 clients, before 54 examiners in 37 art units.
